Contact
Please use this form to send email to PR contact of this press release:
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
TO:
Please use this form to send email to PR contact of this press release:
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
TO: